Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Biotech
Biotech — Sep 7 – Sep 11, 2026 (Wk 37): Biotech Risk Score Rises; Novartis Faces Setback, Encoded Therapeutics Sees Investment →The biotech sector's risk score increased this week, indicating a potentially more volatile environment. Novartis experienced a clinical trial failure, while RTW Biotech Opportunities made an additional investment in Encoded Therapeutics, highlighting continued activity in specific…
EVO
Valuation N/A
Evotec SE
Price$1.68
Model IV—
P/IV—
Limited data — see page
EWTX
Valuation N/A
Edgewise Therapeutics, Inc.
Price$44.40
Model IV—
P/IV—
Limited data — see page
EXEL
Deeply undervalued
EXELIXIS, INC.
Price$56.12
Model IV$88.60
P/IV0.57
Discount 37%
Return to IV: +57.9%
Market implies +5.7%/yr
vs model +15.2% · below model
EXOZ
Valuation N/A
EXOZYMES INC.
Price$6.30
Model IV—
P/IV—
Market implies +95.8%/yr
vs model +15.0% · above model
EYPT
Valuation N/A
EyePoint, Inc.
Price$4.23
Model IV—
P/IV—
Limited data — see page
FATE
Valuation N/A
FATE THERAPEUTICS INC
Price$2.31
Model IV—
P/IV—
Market implies +92.2%/yr
vs model +2.0% · above model
FBIO
Deeply overvalued
Fortress Biotech, Inc.
Price$2.52
Model IV$1.22
P/IV2.30
Premium +107%
Return to IV: -51.8%
Market implies +6.0%/yr
vs model +2.0% · above model
FBLG
Valuation N/A
FibroBiologics, Inc.
Price$1.61
Model IV—
P/IV—
Limited data — see page
FBRX
Valuation N/A
Forte Biosciences, Inc.
Price$76.99
Model IV—
P/IV—
Limited data — see page
FDMT
Deeply overvalued
4D Molecular Therapeutics, Inc.
Price$13.17
Model IV$8.25
P/IV1.20
Premium +60%
Return to IV: -37.4%
Market implies +5.4%/yr
vs model +47.4% · below model
FENC
Valuation N/A
FENNEC PHARMACEUTICALS INC.
Price$10.64
Model IV—
P/IV—
Market implies +32.2%/yr
vs model +15.0% · above model
FHTX
Deeply overvalued
Foghorn Therapeutics Inc.
Price$4.36
Model IV$1.32
P/IV3.25
Premium +231%
Return to IV: -69.8%
Market implies +21.7%/yr
vs model +50.0% · below model
FLNA
Valuation N/A
FILANA THERAPEUTICS, INC.
Price$0.77
Model IV—
P/IV—
Limited data — see page
FTRE
Undervalued
Fortrea Holdings Inc.
Price$17.20
Model IV$18.82
P/IV0.82
Discount 9%
Return to IV: +9.4%
Market implies +3.3%/yr
vs model +2.0% · in line
FULC
Valuation N/A
Fulcrum Therapeutics, Inc.
Price$3.78
Model IV—
P/IV—
Limited data — see page
GALT
Valuation N/A
GALECTIN THERAPEUTICS INC
Price$3.91
Model IV—
P/IV—
Limited data — see page
GDTC
Valuation N/A
CytoMed Therapeutics Ltd
Price$0.78
Model IV—
P/IV—
Limited data — see page
GELS
Valuation N/A
Gelteq Ltd
Price$0.70
Model IV—
P/IV—
Limited data — see page
GENB
Valuation N/A
Generate Biomedicines, Inc.
Price$15.72
Model IV—
P/IV—
Limited data — see page
GERN
Valuation N/A
GERON CORP
Price$1.35
Model IV—
P/IV—
Market implies +141.6%/yr
vs model +15.0% · above model
GH
Deeply overvalued
Guardant Health, Inc.
Price$157.38
Model IV$27.95
P/IV4.64
Premium +463%
Return to IV: -82.2%
Market implies +19.7%/yr
vs model +27.3% · below model
GHRS
Valuation N/A
GH Research PLC
Price$27.20
Model IV—
P/IV—
Limited data — see page
GILD
Fairly valued
GILEAD SCIENCES, INC.
Price$146.41
Model IV$157.63
P/IV0.85
Discount 7%
Return to IV: +7.7%
Market implies +2.9%/yr
vs model +4.3% · in line
GLMD
Valuation N/A
Galmed Pharmaceuticals Ltd.
Price$3.84
Model IV—
P/IV—
Limited data — see page
GLSI
Valuation N/A
Greenwich LifeSciences, Inc.
Price$16.09
Model IV—
P/IV—
Limited data — see page
GLUE
Valuation N/A
Monte Rosa Therapeutics, Inc.
Price$14.07
Model IV—
P/IV—
Market implies +25.8%/yr
vs model +15.0% · above model
GMAB
Valuation N/A
GENMAB A/S
Price$32.47
Model IV—
P/IV—
Limited data — see page
GNLX
Valuation N/A
GENELUX Corp
Price$2.49
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
GNPX
Valuation N/A
Genprex, Inc.
Price$3.45
Model IV—
P/IV—
Limited data — see page
GNTA
Valuation N/A
Genenta Science S.p.A.
Price$0.83
Model IV—
P/IV—
Limited data — see page
GOSS
Valuation N/A
Gossamer Bio, Inc.
Price$10.70
Model IV—
P/IV—
Market implies +79.5%/yr
vs model +15.0% · above model
GOVX
Deeply undervalued
GeoVax Labs, Inc.
Price$0.42
Model IV$6.80
P/IV0.30
Discount 94%
Return to IV: +1,525.4%
Market implies -50.0%/yr
vs model +50.0% · below model
GPCR
Valuation N/A
Structure Therapeutics Inc.
Price$38.66
Model IV—
P/IV—
Limited data — see page
GRCE
Valuation N/A
Grace Therapeutics, Inc.
Price$2.22
Model IV—
P/IV—
Market implies -18.8%/yr
vs model +15.0% · below model
GRDX
Valuation N/A
GridAI Technologies Corp.
Price$2.86
Model IV—
P/IV—
Market implies +59.5%/yr
vs model +15.0% · above model
GRFS
Valuation N/A
Grifols SA
Price$7.48
Model IV—
P/IV—
Limited data — see page
GRI
Valuation N/A
GRI Bio, Inc.
Price$1.89
Model IV—
P/IV—
Limited data — see page
GRML
Valuation N/A
Greenland Mines Ltd
Price$3.15
Model IV—
P/IV—
Limited data — see page
GRMLW
Valuation N/A
Greenland Mines Ltd
Price$0.20
Model IV—
P/IV—
Limited data — see page
GRX
Valuation N/A
Gabelli Healthcare & WellnessRx Trust
Price$9.72
Model IV—
P/IV—
Limited data — see page
GTBP
Valuation N/A
GT Biopharma, Inc.
Price$11.63
Model IV—
P/IV—
Limited data — see page
HALO
Deeply undervalued
HALOZYME THERAPEUTICS, INC.
Price$107.94
Model IV$316.93
P/IV0.21
Discount 66%
Return to IV: +193.6%
Market implies +4.8%/yr
vs model +25.0% · below model
HBIO
Valuation N/A
HARVARD BIOSCIENCE INC
Price$8.03
Model IV—
P/IV—
Market implies +37.0%/yr
vs model +2.0% · above model
HCM
Valuation N/A
HUTCHMED (China) Ltd
Price$12.82
Model IV—
P/IV—
Market implies +23.2%/yr
vs model +11.4% · above model
HCWB
Valuation N/A
HCW Biologics Inc.
Price$2.24
Model IV—
P/IV—
Market implies +29.2%/yr
vs model +15.0% · above model
HELP
Valuation N/A
CYBIN INC.
Price$13.12
Model IV—
P/IV—
Limited data — see page
HIND
Valuation N/A
Vyome Holdings, Inc
Price$2.06
Model IV—
P/IV—
Market implies +63.7%/yr
vs model +2.0% · above model
HKPD
Valuation N/A
Cellyan Biotechnology Co., Ltd
Price$0.13
Model IV—
P/IV—
Limited data — see page
HOTH
Valuation N/A
Rocket One Inc.
Price$0.68
Model IV—
P/IV—
Limited data — see page
HOWL
Valuation N/A
Werewolf Therapeutics, Inc.
Price$0.96
Model IV—
P/IV—
Limited data — see page
HQH
Valuation N/A
abrdn Healthcare Investors
Price$21.76
Model IV—
P/IV—
Limited data — see page
HQL
Valuation N/A
abrdn Life Sciences Investors
Price$19.76
Model IV—
P/IV—
Limited data — see page
HUMA
Valuation N/A
Humacyte, Inc.
Price$0.57
Model IV—
P/IV—
Market implies +69.5%/yr
vs model +15.0% · above model
HUMAW
Valuation N/A
HUMAW
Price$0.00
Model IV—
P/IV—
Limited data — see page
HURA
Valuation N/A
TuHURA Biosciences, Inc./NV
Price$2.05
Model IV—
P/IV—
Limited data — see page
HYFT
Valuation N/A
MindWalk Holdings Corp.
Price$1.31
Model IV—
P/IV—
Limited data — see page
HYPD
Valuation N/A
HYPERION DEFI, INC.
Price$3.49
Model IV—
P/IV—
Market implies +92.8%/yr
vs model +2.0% · above model
IBIO
Valuation N/A
iBio, Inc.
Price$1.21
Model IV—
P/IV—
Market implies +55.1%/yr
vs model +2.0% · above model
IBO
Valuation N/A
IMPACT BIOMEDICAL INC.
Price$0.46
Model IV—
P/IV—
Market implies +85.3%/yr
vs model +2.0% · above model
IBRX
Valuation N/A
ImmunityBio, Inc.
Price$7.91
Model IV—
P/IV—
Market implies +44.8%/yr
vs model +50.0% · below model